Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 12/20 | 0.46 |
| ▸ | CTSK | P43235 | 11/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607238 | 0.94 | ABCB1 (0.46) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL31248043 | 0.90 | ABCB1 (0.51) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL24817612 | 0.88 | CTSS (0.45) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL31247975 | 0.87 | ABCB1 (0.41) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL30930720 | 0.84 | ACE (0.42) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL30892072 | 0.82 | PSEN1 (0.42) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL29757417 | 0.82 | ITGB3 (0.47) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL5096778 | 0.82 | CTSS (0.58) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL14264232 | 0.82 | CTSS (0.58) | ABCB1CTSSCTSKCTSBCTSL | |
| SCHEMBL31501260 | 0.81 | ABCB1 (0.41) | ABCB1CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092769-A1 | PREPARATION METHOD FOR DUAL GIP AND GLP-1 RECEPTOR AGONIST | 博瑞生物医药（苏州）股份有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-117946243-A | Preparation method of Tirzepatide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| EP-4685157-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685156-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025092769-A1 | PREPARATION METHOD FOR DUAL GIP AND GLP-1 RECEPTOR AGONIST | 博瑞生物医药（苏州）股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118108791-A | Synthetic method of Boc-Tyr (tBu) -Aib-Glu (OtBu) -Gly-OH | 成都普康唯新生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108791-A | Synthetic method of Boc-Tyr (tBu) -Aib-Glu (OtBu) -Gly-OH | 成都普康唯新生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117946243-A | Preparation method of Tirzepatide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946243-A | Preparation method of Tirzepatide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230158468-A1 | THREE RESIN REACTORS IN SERIES PEPTIDE SYNTHESIZER | ELI LILLY AND COMPANY | 2023-05-25 | — | — | US | disclosed |
| CN-115651075-B | Synthesis method of Tirzepatide | 杭州信海医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115651075-A | Synthesis method of Tirzepatide | 杭州信海医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158468-A1 | THREE RESIN REACTORS IN SERIES PEPTIDE SYNTHESIZER | SRMS, PTMS, PNISR | ABCB1 4643/4885CTSS 61/4885CTSK 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.